REUMAT

By Richard Mark Kirkner Rituximab doses as low as 200 mg reduced disease activity in patients with rheumatoid arthritis to an extent that’s similar to the standard 1,000-mg dose during more than 3 years of follow-up, according to results from an extension study of a clinical trial in the Netherlands. Nathan den Broeder “We could not formally statistically […]

After: Paul L Romain, MDMonica Ramirez Curtis, MD, MPH Cardiovascular and malignancy risk with Janus kinase inhibitors (September 2021) The level of risk for cardiovascular (CV) events and malignancy with Janus kinase (JAK) inhibitors is uncertain. Unpublished data from a phase 4 open-label trial comparing tofacitinib with a tumor necrosis factor (TNF) inhibitor in over 4300 patients […]